Shire has entered into a joint development and commercialisation agreement worth US$498 M with Acceleron Pharma to develop drugs to treat rare muscle disorders, including Duchenne muscular dystrophy. The agreement includes ACE-031, which targets the activin receptor IIB pathway and is the subject of a Phase IIa trial.